MAXCYTE, INC.

MXCT Nasdaq CIK: 0001287098

Company Information

Industry Services-Commercial Physical & Biological Research
SIC Code 8731
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 9713 KEY WEST AVENUE,, ROCKVILLE, MD, 20850
Mailing Address 9713 KEY WEST AVENUE,, ROCKVILLE, MD, 20850
Phone 301-517-5556
Fiscal Year End 1231
EIN 522210438

Financial Overview

FY2025 FY

$38.63M
Revenue
$33.22M
Total Liabilities
$232.17M
Stockholders' Equity
$27.88M
Cash & Equivalents
$-0.42
EPS

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 31, 2026 View on SEC
8-K Current report of material events March 27, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 27, 2026 View on SEC
10-K Annual financial report March 25, 2026 View on SEC
8-K Current report of material events March 24, 2026 View on SEC
8-K Current report of material events March 20, 2026 View on SEC
4 Insider stock transaction report March 19, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 5, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment January 21, 2026 View on SEC

Annual Reports

10-K March 25, 2026
  • Provides essential electroporation technology for the growing cell therapy and gene editing markets.
  • Maintains 22 Strategic Platform Licenses, providing a foundation for long-term recurring revenue.
View Analysis

Material Events

8-K Financial Distress March 20, 2026
High Impact
  • Global cell-engineering company with Flow Electroporation® technology.
  • Technology helps drug companies develop cell-based therapies.
View Analysis

Insider Trading

SELL 1 insiders 1 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 8731)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.